Avalo Therapeutics, Inc. — fact timeline

Avalo Therapeutics, Inc. issued 4,294.675 shares of preferred stock to an accredited investor.

“On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per share (the “Series C-1 Preferred Stock”), such exchange, the “Exchange”.”

Avalo Therapeutics, Inc.: Filed Certificate of Designation to designate Series C-1 Preferred Stock (effective 2026-06-11).

“On June 11, 2026, in connection with the Exchange, the Company filed a Certificate of Designation to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Designation”), with the Secretary of State of the State of Delaware for the purpose of designating the Series C-1 Preferred Stock.”

Avalo Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-02 meeting.

“3. Proposal 3: To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This proposal was approved by the votes indicated below. For Against Abstain Broker Non-Votes 22,513,332 153,320 5,632 —”

Avalo Therapeutics, Inc. shareholders approved To approve the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) at the 2026-06-02 meeting.

“2. Proposal 2: To approve the A&R 2016 ESPP . This proposal was approved by the votes indicated below: For Against Abstain Broker Non-Votes 14,513,683 6,588,576 343 1,569,682”

Avalo Therapeutics, Inc. shareholders approved Election of seven nominees to the Board to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified. at the 2026-06-02 meeting.

“1. Proposal 1: To elect seven nominees to the Board to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following nominees were elected to the Board, with the voting results for each nominee as shown: Name For Withheld Broker Non-Votes Michael Heffernan 21,101,978 624 — Garry Neil, M.D. 21,101,093 1,509 — Rita Jain, M.D. 21,101,289 1,313 — Aaron Kantoff 21,078,660 23,942 — Gilla Kaplan, Ph.D. 21,093,059 9,543 — Kevin Lind 21,101,989 613 — Samantha Truex 21,089,975 12,627 —”

Avalo Therapeutics, Inc. reported first quarter 2026 results: net income Net loss was $19.6 million, EPS Basic and diluted net loss per share was $0.98.

“On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Avalo Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters valued at approximately $405.0 million (effective 2026-05-05).

“On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).”

Avalo Therapeutics, Inc. amended Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization with AlmataBio, Inc. and Patrick J. Crutcher, solely as representative agent and attorney-in-fact of the former holders of securities in AlmataBio valued at $2.25 million (effective 2026-04-26).

“On April 26, 2026 (the “ Effective Date ”), Avalo Therapeutics, Inc. (the “ Company ”) entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization (the “ Milestone Buyout and Amendment Agreement ”).”

Avalo Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net loss was $78.3 million for the year ended December 31, 2025, EPS Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025.

“On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”

Rita Jain was appointed as Director at Avalo Therapeutics, Inc..

“On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.”

Michael Heffernan was appointed as Chairman of the Board at Avalo Therapeutics, Inc..

“On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.”

Jennifer Riley was appointed as Chief Strategy Officer at Avalo Therapeutics, Inc..

“On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.”

Mittie Doyle was appointed as Chief Medical Officer at Avalo Therapeutics, Inc..

“On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.”

Paul Varki was appointed as Chief Legal Officer at Avalo Therapeutics, Inc..

“On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.”

Avalo Therapeutics, Inc. reported first quarter of 2024 results: net income net loss of $121.3 million.

“For the three months ended March 31, 2024, Avalo generated a net loss of $121.3 million.”

Avalo Therapeutics, Inc. completed an acquisition involving AlmataBio, Inc. for 171,605 shares of Common Stock and 2,412 shares of Series C Preferred Stock valued at approximately $15 million (closed 2024-03-27).

“or employee of the Company or the Subsidiary following completion of the Merger. As consideration for the Merger, the Company issued to the Almata stockholders an aggregate of 171,605 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and an aggregate of 2,412 shares of Series C Preferred Stock (as defined and described in”

Samantha Truex was appointed as Director at Avalo Therapeutics, Inc..

“the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024”

Aaron Kantoff was appointed as Director at Avalo Therapeutics, Inc..

“the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024”

Jonathan Goldman was appointed as Director at Avalo Therapeutics, Inc..

“Jonathan Goldman was appointed to the Board.”

Avalo Therapeutics, Inc.: Effected a reverse stock split at a ratio of 1-for-240 shares of common stock (effective 2023-12-28).

“Avalo Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one (1) share for every two hundred forty (240) shares outstanding”

Avalo Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-20 meeting.

“Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm”

Avalo Therapeutics, Inc. shareholders approved Approval of an Amendment to our Certificate of Incorporation to Effect a Reverse Stock Split at the 2023-12-20 meeting.

“Proposal 2: Approval of an Amendment to our Certificate of Incorporation to Effect a Reverse Stock Split”

Avalo Therapeutics, Inc. shareholders approved Election of Directors at the 2023-12-20 meeting.

“Proposal 1: Election of Directors By the vote reflected below, the Company’s stockholders elected each of the following individuals to the Board to hold office until the 2024 Annual Meeting and until their respective successors are elected and qualified.”

Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2), 5550(b)(1)).

“November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55”

Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C)).

“November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55”

Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 9, 2023, Avalo Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2023.”

Avalo Therapeutics, Inc. completed a disposition involving AUG Therapeutics, LLC for $150,000 upfront plus contingent milestone payments (closed 2023-10-27).

“previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG paid an upfront payment of $150,000, as well as, for each compound, is obligated to make a contingent milestone payment of $15,000,000 (for a potential aggregate of $45 million) if the first Food and Drug”

Avalo Therapeutics, Inc.: Amended quorum requirement for stockholder meetings from majority of shares present to one-third of shares entitled to vote (effective 2023-10-16).

“On October 16, 2023, the Board of Directors of Avalo Therapeutics, Inc. (the “Company”) approved the Company’s Fourth Amended and Restated Bylaws, effective immediately upon approval by the Board (the “Amended and Restated Bylaws”).”

Avalo Therapeutics, Inc. amended Note Amendment with Holders (effective 2023-09-13).

“the Company agreed to amend the Note to grant to the Holders a security interest in the Company’s owned patents and trademarks (the “Note Amendment”).”

Avalo Therapeutics, Inc. entered into Third Forbearance Agreement with Holders (effective 2023-09-13).

“On September 13, 2023, the Company and the Holders entered into a Third Forbearance Agreement (the “Third Forbearance Agreement”) to, among other things, further extend the forbearance period until October 15, 2023.”

Avalo Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C), 5810(c)(3)(A)(iii)).

“September 12, 2023, the Company received notice (the “September 12 Letter”) from Nasdaq that Nasdaq had determined that as of September 11, 2023, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days triggering application of Listing Rule 5810(c)(3)(A)(iii) which states in part: if during any compliance period specified in Rule 5810(c)(3)(A), a company’s security has a closing bid price of $0.10 or less for ten consecutive trading days, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810 with respect to”

Avalo Therapeutics, Inc. entered into Asset Purchase Agreement with AUG Therapeutics, LLC valued at an upfront payment of $150,000 (effective 2023-09-11).

“On September 11, 2023, Avalo Therapeutics, Inc. (the " Company ") entered into an Asset Purchase Agreement (the " Purchase Agreement ") with AUG Therapeutics, LLC”

Avalo Therapeutics, Inc. entered into Second Forbearance Agreement with Holders valued at forbearance period extended to September 15, 2023; cash deposit set at $3,000,000 without addition o (effective 2023-08-14).

“On August 14, 2023, the Company and the Holders entered into a Second Forbearance Agreement (the “Second Forbearance Agreement”) whereby the forbearance period was extended to September 15, 2023.”

Avalo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“August 8, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Avalo Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market pursuant to Na”

Avalo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 8, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Avalo Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market pursuant to Na”

Avalo Therapeutics, Inc. amended Amendment No. 1 to the Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-08-07).

“On August 7, 2023, the Company and Oppenheimer entered into Amendment No. 1 to the Sales Agreement (the “Amendment”, and together with the Sales Agreement, the “Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of August 7, 2023 under the Amended Sales Agreement, the Company may offer and sell additional shares of common stock having an aggregate offering price of up to $50,000,000”

Avalo Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

“On August 3, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”

Avalo Therapeutics, Inc. entered into Forbearance Agreement with the Holders (effective 2023-07-20).

“As of July 20, 2023, the Holders asserted that a default and event of default has occurred due to a material adverse change in the Company’s business (the “Existing Default”).”

Avalo Therapeutics, Inc. entered into Exchange Agreement with entities affiliated with Venrock Healthcare Capital Partners (effective 2023-05-31).

“On May 31, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with entities affiliated with Venrock Healthcare Capital Partners (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,300,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,300,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.001 per share.”

Avalo Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $475, net income $(9,955), EPS $(0.85).

“Product revenue, net $ 475 $ 1,173 Total revenues, net 475 1,173 Operating expenses: Cost of product sales 551 720 Research and development 6,008 9,584 Selling, general and administrative 2,708 11,684 Amortization expense — 38 Total operating expenses 9,267 22,026 (8,792) (20,853) Other expense: Interest expense, net (949) (1,169) Change in fair value of derivative liability (180) — Other expense, net (26) (20) Total other expense, net (1,155) (1,189) Loss before taxes (9,947) (22,042) Income tax expense 8 9 Net loss and comprehensive loss $ (9,955) $ (22,051) Net loss per share of common stock, basic and diluted 1 $ (0.85) $ (2.35)”

Avalo Therapeutics, Inc. entered into Sales Agreement with Oppenheimer & Co. Inc. valued at up to $9,032,567 (effective 2023-05-04).

“On May 4, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Oppenheimer, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $9,032,567 (the “Offering”).”

Avalo Therapeutics, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC valued at Termination of Controlled Equity Offering Sales Agreement (up to $50.0 million aggregate offering pr (effective 2023-04-30).

“Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed in July 2021, Avalo Therapeutics, Inc. (the “Company”), entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and RBC Capital Markets, LLC (“RBC”, and collectively with Cantor, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million. On April 20, 2023, the Company delivered written notice to Cantor and RBC to terminate the Sales Agreement, effective no later than April 30, 2023, pursuant to Section 12(b) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by referen”

Avalo Therapeutics, Inc. reported financial results for the year ended December 31, 2022.

“On March 29, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.”

Avalo Therapeutics, Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $15 million (effective 2023-02-02).

“On February 2, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the public offering (the “Offering”) of an aggregate of 3,770,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a combined price to the public of $3.98 per share and warrant, for aggregate gross proceeds of approximately $15 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the Offering.”

Avalo Therapeutics, Inc. completed a disposition involving ES Therapeutics, LLC for $5.0 million (closed 2022-11-10).

“The transaction closed on November 10, 2022 and the Company has received the $5.0 million payment from ES.”

Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

“Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.”

Garry Neil was appointed as Chairman of the Board at Avalo Therapeutics, Inc..

“The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.”

Keith Maher resigned as Director at Avalo Therapeutics, Inc..

“On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.”

Steven Boyd resigned as Director at Avalo Therapeutics, Inc..

“On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.”

Christopher Sullivan was appointed as Chief Financial Officer at Avalo Therapeutics, Inc..

“On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.”